Regeneron Pharmaceuticals (NASDAQ:REGN – Get Free Report) and Orchestra BioMed (NASDAQ:OBIO – Get Free Report) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, risk, dividends, analyst recommendations, earnings and profitability.
Profitability
This table compares Regeneron Pharmaceuticals and Orchestra BioMed’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Regeneron Pharmaceuticals | 31.37% | 15.06% | 11.77% |
| Orchestra BioMed | -2,367.49% | -289.42% | -110.04% |
Earnings & Valuation
This table compares Regeneron Pharmaceuticals and Orchestra BioMed”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Regeneron Pharmaceuticals | $14.20 billion | 4.37 | $4.41 billion | $39.68 | 14.76 |
| Orchestra BioMed | $2.64 million | 40.54 | -$61.02 million | ($1.83) | -1.51 |
Regeneron Pharmaceuticals has higher revenue and earnings than Orchestra BioMed. Orchestra BioMed is trading at a lower price-to-earnings ratio than Regeneron Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Analyst Recommendations
This is a breakdown of current ratings and price targets for Regeneron Pharmaceuticals and Orchestra BioMed, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Regeneron Pharmaceuticals | 1 | 7 | 18 | 3 | 2.79 |
| Orchestra BioMed | 1 | 1 | 3 | 1 | 2.67 |
Regeneron Pharmaceuticals currently has a consensus price target of $817.67, suggesting a potential upside of 39.66%. Orchestra BioMed has a consensus price target of $13.50, suggesting a potential upside of 387.36%. Given Orchestra BioMed’s higher possible upside, analysts plainly believe Orchestra BioMed is more favorable than Regeneron Pharmaceuticals.
Risk and Volatility
Regeneron Pharmaceuticals has a beta of 0.31, suggesting that its share price is 69% less volatile than the S&P 500. Comparatively, Orchestra BioMed has a beta of 0.6, suggesting that its share price is 40% less volatile than the S&P 500.
Institutional & Insider Ownership
83.3% of Regeneron Pharmaceuticals shares are held by institutional investors. Comparatively, 53.2% of Orchestra BioMed shares are held by institutional investors. 7.0% of Regeneron Pharmaceuticals shares are held by company insiders. Comparatively, 8.1% of Orchestra BioMed shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Summary
Regeneron Pharmaceuticals beats Orchestra BioMed on 11 of the 15 factors compared between the two stocks.
About Regeneron Pharmaceuticals
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.
About Orchestra BioMed
Orchestra BioMed Holdings, Inc. operates as a biomedical innovation company. The company’s flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension (HTN); and Virtue Sirolimus AngioInfusion Balloon (SAB) for the treatment of atherosclerotic artery disease. Its products also comprise FreeHold devices and minimally invasive surgery devices. The company has a collaboration agreement with Medtronic, Inc. for the development and commercialization of BackBeat CNT for the treatment of HTN in patients indicated for a cardiac pacemaker; and a strategic collaboration with Terumo Medical Corporation for the development and commercialization of Virtue SAB for the treatment of coronary and peripheral artery disease. Orchestra BioMed Holdings, Inc. is based in New Hope, Pennsylvania.
Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
